Citations

Clear

3042 citation(s) found for "Kumar, S".

Shifts in Serum Bile Acid Profiles Associated With Barrett's Esophagus and Stages of Progression to Esophageal Adenocarcinoma
Kumar, Aarti , Gwalani, Pranav , Iyer, Prasad G. , Wang, Kenneth K. , Ginsberg, Gregory G. , Lightdale, Charles J. , Portillo, Armando Del , Lagana, Stephen M. , Jin, Zhezhen , Rustgi, Anil K. , Quante, Michael , Falk, Gary W. , Li, Yun , Li, Hongzhe , Genkinger, Jeanine M. , Wang, Timothy C. , Wang, Harris H. , Abrams, Julian A

Mayo Clinic

Clinical and Translational Gastroenterology | August 22, 2024 | Volume: 15 | Issue: 10 | Pages: e1

10.14309/ctg.0000000000000762 | PMID 39166758 Get It

INTRODUCTION: Reflux bile acids are believed to promote esophageal adenocarcinoma (EAC), but the role of systemic bile acids is unknown. This study aimed to assess associations between systemic bile acids and stages of Barrett's esophagus (BE) progression. METHODS: Subjects with and without BE were enrolled in this multicenter cross-sectional study. Targeted serum bile acid profiling was performed, and a subset of subjects completed a validated food frequency questionnaire. RNA sequencing was performed on BE or gastric cardia tissue to assess bile acid associations with gene expression. RESULTS: A total of 141 subjects were enrolled with serum bile acids profiled (49 non-BE; 92 BE: 44 no dysplasia, 25 indefinite/low grade dysplasia, 23 high-grade dysplasia/EAC). Lower Healthy Eating Index score, older age, higher body mass index, and no proton pump inhibitor use were associated with increased levels of multiple bile acids. Global bile acid pools were distinct between non-BE and stages of BE neoplasia ( P = 0.004). Increasing cholic acid was associated with high-grade dysplasia/EAC compared with non-BE, even after adjusting for EAC risk factors (adjusted odds ratio 2.03, 95% confidence interval 1.11–3.71) as was the combination of unconjugated primary bile acids (adjusted odds ratio 1.81, 95% confidence interval 1.04–3.13). High cholic acid levels were associated with tissue gene expression changes including increased DNA replication and reduced lymphocyte differentiation genes. DISCUSSION: Alterations in serum bile acids are independently associated with advanced neoplasia in BE and may contribute to neoplastic progression. Future studies should explore associated gut microbiome changes, proneoplastic effects of bile acids, and whether these bile acids, particularly cholic acid, represent potential biomarkers or viable therapeutic targets for advanced neoplasia in BE.
Thrombolysis for Ischemic Stroke Despite Recent Ingestion of Direct Oral Anticoagulants – A Growing Dilemma Also in India
Meinel, Thomas R. , Menon, Bijoy K. , Fischer, Urs , Seiffge, David , Paramasivan, Naveen K, Fischer, Urs , Seiffge, David , Paramasivan, Naveen Kumar

Mayo Clinic

Annals of Indian Academy of Neurology | August 20, 2024 | Volume: 27 | Issue: 4 | Pages: 345-351

10.4103/aian.aian_524_24 | PMID 39196805 Get It

The administration of intravenous thrombolysis (IVT) for patients with acute ischemic stroke who have recently ingested direct oral anticoagulants (DOACs) presents a clinical challenge due to the perceived increased risk of intracranial hemorrhage (ICH). Traditional guidelines from the US and European authorities advise against IVT within 48 h of last DOAC ingestion, unless specific coagulation tests indicate safety. However, emerging observational studies suggest that IVT might be safe in selected patients. A US stroke registry study and a global multicenter cohort study both reported no significant increase in symptomatic ICH among patients on DOACs compared to those not on anticoagulants. A systematic review of all published observational studies further supported these findings, showing comparable bleeding rates and functional outcomes in DOAC-treated patients. Reversal agents like idarucizumab for dabigatran have demonstrated potential in facilitating safer IVT administration, though logistical and cost-related barriers limit their widespread use. The variability in global guidelines reflects differing approaches to risk assessment and resource availability, highlighting the need for individualized treatment decisions. In India, the increasing prevalence of atrial fibrillation and stroke as well as prescription of DOACs necessitate adapted guidelines that consider local health-care infrastructure. Despite the promising observational data, the lack of randomized controlled trials underscores the need for further research to establish robust evidence for IVT use in this context. Collaborative international efforts and inclusion of diverse patient populations in future studies will be crucial to refine treatment protocols and improve outcomes for stroke patients on DOACs.
Molecular Susceptibility and Treatment Challenges in Melanoma
Kolathur, Kiran Kumar , Nag, Radhakanta , Shenoy, P. , Malik, Yagya, Varanasi, Sai Manasa , Angom, Ramcharan Singh , Mukhopadhyay, Debabrata , Shenoy, Prathvi V , Mukhopadhyay, Debabrata , Singh Angom, Ramcharan

Mayo Clinic

Cells | August 20, 2024 | Volume: 13 | Issue: 16 | Pages: 1383

10.3390/cells13161383 | PMID 39195270 Get It

Melanoma is the most aggressive subtype of cancer, with a higher propensity to spread compared to most solid tumors. The application of OMICS approaches has revolutionized the field of melanoma research by providing comprehensive insights into the molecular alterations and biological processes underlying melanoma development and progression. This review aims to offer an overview of melanoma biology, covering its transition from primary to malignant melanoma, as well as the key genes and pathways involved in the initiation and progression of this disease. Utilizing online databases, we extensively explored the general expression profile of genes, identified the most frequently altered genes and gene mutations, and examined genetic alterations responsible for drug resistance. Additionally, we studied the mechanisms responsible for immune checkpoint inhibitor resistance in melanoma.
Point-of-care ultrasound training in nephrology: a position statement by the International Alliance for POCUS in Nephrology
Koratala, Abhilash , Argaiz, Eduardo R. , Anwar, Siddiq , Beaubien‐Souligny, William , Bhasin, Bhavna , Diniz, Hugo , Gallardo, Marco Vaca , Torres, Fredzzia Graterol, Hanko, Jennifer , Jaberi, Aala, Kazory, Amir , Raina, Rupesh, Villavicencio-Cerón, Vanessa, Beaubien-Souligny, William , Husain-Syed, Faeq , Sethi, Sidharth Kumar , Koratala, Abhilash , Romero‐González, Gregorio , Reisinger, Nathaniel C. , Husain‐Syed, Faeq , Raina, Rupesh , Ronco, Claudio , Salgado, Octavio J. , Villavicencio-Cerón, Vanessa, Yadla, Manjusha , Bastos, Marcus Gomes

Mayo Clinic

Clinical Kidney Journal | August 14, 2024 | Volume: 17 | Issue: 11 | Pages: No page available

10.1093/ckj/sfae245 | PMID 39502372 Get It

ABSTRACT Point-of-care ultrasonography (POCUS) has rapidly evolved from a niche technology to an indispensable tool across medical specialties, including nephrology. This evolution is driven by advancements in technology and the visionary efforts of clinicians in emergency medicine and beyond. Recognizing its potential, medical schools are increasingly integrating POCUS into training curricula, emphasizing its role in enhancing diagnostic accuracy and patient care. Despite these advancements, barriers such as limited faculty expertise and ‘lack of’ standardized guidelines hinder widespread adoption and regulation. The International Alliance for POCUS in Nephrology (IAPN), through this position statement, aims to guide nephrologists in harnessing the diagnostic power of POCUS responsibly and effectively. By outlining core competencies, recommending training modalities and advocating for robust quality assurance measures, we envision a future where POCUS enhances nephrology practice globally, ensuring optimal patient outcomes through informed, evidence-based decision-making. International collaboration and education are essential to overcome current challenges and realize the full potential of POCUS in nephrology and beyond.
Technical Quality of Contemporary Endoscopic Sinus Surgery: An Assessment by Study of Anatomical Features Needing Attention at Revision Surgery
Kumar, Nitish , Gomes, Pedro Lança , Marino, Michael J. , Miglani, Amar , Kumar, Nitish , Marino, Michael J , Lança Gomes, Pedro , Lal, Devyani

Mayo Clinic

Sinusitis | August 14, 2024 | Volume: 8 | Issue: 2 | Pages: 28-36

10.3390/sinusitis8020005 Get It

Although technical causes of endoscopic sinus surgery (ESS) failure have long been reported, we were curious about the quality of contemporary sinus surgery. The electronic health database of Mayo Clinic, Arizona was scrutinized to identify adult patients with diffuse chronic rhinosinusitis (CRS) who underwent revision ESS between January 2019 and September 2023 with a history of bilateral full-house ESS. Anatomical features on preoperative radiology and intraoperative endoscopy were cataloged: residual uncinate tissue, maxillary antrostomy with a non-incorporated natural os, residual ethmoidal septations (three septations > 3 mm), and inadequate sphenoid osteotomy (os size < 6 mm). Sixty-nine subjects were identified. A deviated nasal septum was present in 53.6%. Residual uncinate tissue was noted in 50.7% of patients associated with missed natural maxillary os in 39.13% of antrostomies. An inadequate os diameter was noted in 63.8% of sphenoidotomies. Significant residual septations were seen in posterior ethmoidal cells in 66.7% and anterior ethmoidal cells in 62.3% of patients. Residual frontoethmoidal cells were noted in 72.4% of patients. Although the extent of ESS must be individualized, a high prevalence of features reflecting suboptimal surgery that could limit the success of ESS was identified. These findings merit further consideration for focused training during residency and continuous professional development activities.
Gender gap in cardiothoracic surgery randomized controlled trial and post-hoc analysis of randomized controlled trial authorship from 2014 to 2020
Shariff, Mariam , Kumar, Ashish, Stulak, John M., Naumann, Kathryn E, Saddoughi, Sahar A. , Blackmon, Shanda H, Shariff, Mariam , Blackmon, Shanda

Mayo Clinic

European Journal of Cardio-Thoracic Surgery | August 5, 2024 | Volume: 66 | Issue: 4 | Pages: No page available

10.1093/ejcts/ezae297 | PMID 39110508 Get It

Abstract OBJECTIVES To estimate gender disparities among first and last authorships in cardiothoracic randomized controlled trials (RCTs) and association of gender with publications in high-impact journals. METHODS PubMed/MEDLINE database was searched from 1 January 2014 to 31 December 2020 using R statistical software via the ‘easyPubMed’ package to retrieve pertinent data. The ‘gender’ package was utilized to determine gender using the United States Social Security Administration Baby Name Data. The percentage of female first and last authors were computed along with determining the uniqueness of the names. The association of gender and publication in high-impact peer-reviewed journals was delineated. Jonckheere’s trend was computed. RESULTS The database search retrieved a total of 4820 RCTs, of which gender was encoded for the first author in 3247 (67%) RCTs, among which 911 (28%) studies had women as first authors, with a similar trend across 7 years (P = 0.23). Gender was encoded for the last author of 3204 (66%) RCTs, of which 622 (19%) studies had women as last authors, with a similar trend across 7 years (P = 0.45). A total of 627 studies were published in high-impact-factor journals, among which 79 (16%) studies had female first authors and 67 (13%) studies had female last authors. CONCLUSIONS There is an obvious gender disparity of first and last authors in cardiothoracic surgery-related RCTs, with a similar trend across 7 years. However, the post-hoc analysis did demonstrate a positive trend with an increase in the number of female first authors, demonstrating progress.
Pulsed Vibro-Acoustic Analysis Technique for Monitoring Bone Health in Preterm Infants: A Pilot Study
Chaudhary, Pradeep Kumar , Rosen, David , Larson, Nicholas B. , Brumbaugh, Jane E. , Fatemi, Mostafa , Gu, Juanjuan, Rosen, David P , Fatemi, Mostafa , Larson, Nicholas B , Brumbaugh, Jane E , Gu, Juanjuan , Alizad, Azra

Mayo Clinic

IEEE Access | August 2, 2024 | Volume: 12 | Issue: No issue available | Pages: 106707-106719

10.1109/access.2024.3437375 | PMID 39148928 Get It

Graded Organ Response and Progression Criteria for Kidney Immunoglobulin Light Chain Amyloidosis
Wisniowski, Brendan , Geyer, Susan, Milani, Paolo , Veelken, Kaya, Kumar, Shaji , Liedtke, Michaela , Dooley, Katharine , Landau, Heather , Petrlik, Erica , Lentzsch, Suzanne , Coltoff, Alexander , Bladé, Joan , Cibeira, María Teresa , Cohen, Oliver C. , Foard, Darren, Gillmore, Jullian, Wechalekar, Ashutosh , Gertz, Morie A., Milani, Paolo , Gillmore, Julian D , Muchtar, Eli , Palladini, Giovanni , Merlini, Giampaolo , Schönland, Stefan , Hegenbart, Ute , Leung, Nelson , Dispenzieri, Angela , Kastritis, Efstathios , Dimopoulos, Meletios Α. , Ulloa, Patricia, Sanchorawala, Vaishali , Szalat, Raphaël , Cohen, Oliver , Gillmore, Julian D. , Lachmann, Helen J. , Wechalekar, Ashutosh D. , Gertz, Morie A.

Mayo Clinic

JAMA Oncology | August 1, 2024 | Volume: 10 | Issue: 10 | Pages: 1362

10.1001/jamaoncol.2024.2629 | PMID 39088206 Get It

ImportanceKidney light chain (AL) amyloidosis is associated with a risk of progression to kidney replacement therapy (KRT) and death. Several studies have shown that a greater reduction in proteinuria following successful anticlonal therapy is associated with improved outcomes.ObjectiveTo validate graded kidney response criteria and their association with kidney and overall survival (OS).Design, Setting, and ParticipantsThis retrospective, multicenter cohort was conducted at 10 referral centers for amyloidosis from 2010 to 2015 and included patients with kidney AL amyloidosis that was evaluable for kidney response and who achieved at least hematologic partial response within 12 months of diagnosis. The median follow-up was 69 (54-88) months. Data analysis was conducted in 2023.ExposureFour kidney response categories based on the reduction in pretreatment 24-hour urine protein (24-hour UP) levels: complete response (kidCR, 24-hour UP ≤200 mg), very good partial response (kidVGPR, &amp;gt;60% reduction in 24-hour UP), partial response (kidPR, 31%-60% reduction), and no response (kidNR, ≤30% reduction). Kidney response was assessed at landmark points (6, 12, and 24 months) and best kidney response.Main Outcomes and MeasuresCumulative incidence of progression to KRT and OS.ResultsSeven-hundred and thirty-two patients (335 women [45.8%]) were included, with a median (IQR) age of 63 (55-69) years. The median (IQR) baseline 24-hour proteinuria and estimated glomerular filtration rate was 5.3 (2.8-8.5) g per 24 hours and 72 (48-92) mL/min/1.73m2, respectively. In a competing-risk analysis, the 5-year cumulative incidence rates of progression to KRT decreased with deeper kidney responses as early as 6 months from therapy initiation (11%, 12%, 2.1%, and 0% for kidNR, kidPR, kidVGPR, and kidCR, respectively; P = .002) and were maintained at 12 months and 24 months and best kidney response. Patients able to achieve kidCR/kidVGPR by 24 months and at best response had significantly better OS compared with kidPR/kidNR. Kidney progression, defined as a 25% or greater decrease in estimated glomerular filtration rate, was associated with cumulative incidence of progression to KRT and OS.Conclusions and RelevanceThe results of this cohort study suggest that graded kidney response criteria offers clinically and prognostically meaningful information for treating patients with kidney AL amyloidosis. The response criteria potentially inform kidney survival based on the depth of reduction in 24-hour proteinuria levels and demonstrate an OS advantage for those able to achieve kidCR/kidVGPR compared with kidPR/kidNR. Taken together, achievement of at least kidVGPR by 12 months is needed to ultimately improve kidney and patient survival.
A Contemporary Review of Blood Transfusion in Critically Ill Patients
Yadav, Sumeet K. , Hussein, Guleid , Liu, Bolun , Vojjala, Nikhil , Warsame, Mohamed , Labban, Mohamad El , Rauf, Ibtisam , Zareen, Tashfia, Zhang, Y , Jain, Shika M., Surani, Salim , Devulapally, Pavan , Bartlett, Brian, Khan, Syed Anjum , Jain, Nitesh , El Labban, Mohamad , Zhang, Yaqi , Surani, Salim , Devulapally, Pavan , Khan, Syed Anjum , Jain, Nitesh Kumar , Yadav, Sumeet Kumar , Liu, Bolun , Hassan, Mohamed Sayed , Usama, Syed Muhammad, Jain, Shika M

Mayo Clinic

Medicina | July 31, 2024 | Volume: 60 | Issue: 8 | Pages: 1247

10.3390/medicina60081247 | PMID 39202529 Get It

Blood transfusion is a common therapeutic intervention in hospitalized patients. There are numerous indications for transfusion, including anemia and coagulopathy with deficiency of single or multiple coagulation components such as platelets or coagulation factors. Nevertheless, the practice of transfusion in critically ill patients has been controversial mainly due to a lack of evidence and the need to consider the appropriate clinical context for transfusion. Further, transfusion carries many risk factors that must be balanced with benefits. Therefore, transfusion practice in ICU patients has constantly evolved, and we endeavor to present a contemporary review of transfusion practices in this population guided by clinical trials and expert guidelines.
Impact of frailty in hospitalized patients undergoing catheter ablation for atrial fibrillation
Ali, Shafaqat , Khlidj, Yehya , Hendricks, Emily , Farooq, Faryal , Alruwaili, Waleed , Keisham, Bijeta , Gonuguntla, Karthik , Sattar, Yasar , Shaik, Ayesha , Brar, Vijaywant , Sorajja, Dan , Dominic, Paari , Helmy, Tarek , Khlidj, Yehya , Sattar, Yasar , Shaik, Ayesha , Dominic, Paari , Kumar, Manoj , Duhan, Sanchit , Asad, Zain Ul Abideen

Mayo Clinic

Journal of Cardiovascular Electrophysiology | July 30, 2024 | Volume: 35 | Issue: 10 | Pages: 1929-1938

10.1111/jce.16383 | PMID 39075813 Get It

Abstract Background Catheter Ablation (CA) is an effective treatment for atrial fibrillation (AF). However, frail elderly patients have been understudied due to their exclusion from landmark trials. Objectives Our study aims to evaluate outcomes in this population. Methods The national readmission database (2016–2020) was queried, and frailty categories were defined based on hospital risk frailty scores ≦5 as low while >5 as intermediate/high frailty (IHF). We used multivariate regression and propensity‐matched analysis to compare outcomes in patients undergoing CA for atrial fibrillation based on frailty index. Results Among 55 936 CAs for AF, 33,248 patients had low frailty, while 22 688 had intermediate/high frailty (IHF). After propensity matching (N 12 448), IHF patients were found to have higher adverse events, including mortality (3% vs. 0.3%, p < .001), stroke (1.9% vs. 0.2%, p < .001), acute heart failure (53.8% vs. 42.2%, p < .001), AKI (42.5% vs. 6.8%, p < .001), pericardial complications (2.8 vs. 1.6%, p < .001), respiratory complications (27.8 vs. 7.2%, p < .001), major adverse cardiovascular events (21.2 vs. 9.4%, p < .001) and net adverse events (76.7 vs. 55%, p < .001). IHF patients had higher readmissions at 30 (15.5 vs. 12.6%, p < .001), 90 (31.9 vs. 25.1%, p < .001), and 180‐day (41 vs. 34.7%, p < .001) intervals. A higher median length of stay (LOS) (7 vs. 3 days, p < .001) and cost ($44 287 vs. $27 517, p < .001) at index admission and subsequent readmissions were also observed ( p < .001). Conclusion Intermediate/high frailty patients undergoing catheter ablation had worse clinical outcomes, higher healthcare burden, and readmission rates. LOS has decreased in both groups from 2016 to 2020; however, total cost has increased.